Abstract
8097 Background: Efficacy results from the phase III trial of pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) for first-line advanced non-small cell lung cancer (NSCLC) demonstrated non...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
